November 6th, 2026The US Drug-Pricing Reset: Competing on Net Value As Medicare negotiation, PBM reform, and cash-pay channels converge, winning on auditable net value matters more than cutting list prices.Read more
November 6th, 2026Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.Read more
November 11th, 2026FDA Approves Pimjetmi for Patients With Tenosynovial Giant Cell TumorFDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors. Read more
November 10th, 2026FDA Requests Updated Safety Label Warning Across All GLP-1 Receptor Agonist for Potential Risk of NAION FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION. Read more
November 10th, 2026FDA Approves asundexian for Secondary Stroke Risk Reduction FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention. Read more
November 9th, 2026Single Partner Platforms: Enhancing the Prescription Journey for ManufacturersSingle-partner platforms can unify manufacturers, prescribers, and patients to eliminate gaps, cut costs, and boost treatment adherence.Read more
November 9th, 2026argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering. Read more
November 5th, 2026ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 MillionANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.Read more